The KARI fellow will conduct translational imaging research and clinical trials in Alzheimer’s disease. This includes clinical training in the diagnosis and evaluation of dementia using magnetic resonance imaging (MRI) and positron emission tomography (PET), as well as didactic and experiential training in imaging research methods, imaging biomarkers in clinical trials of dementia, and ethical conduct of research. Fellows will gain knowledge in the basic and clinical science of dementia and neurodegeneration, MRI and PET physics, and experience with novel PET tracers in neurodegeneration, including molecular imaging with both metabolic, amyloid, and tau agents. Special emphasis will be on the role of imaging biomarkers in clinical trials, including study design, human subjects protection, and regulatory submissions for human studies. In addition to imaging of dementia, the KARI Program is closely linked to world-renowned collaborators involved in clinical, cerebrospinal fluid (CSF) biomarker, informatics, and genetics research in Alzheimer’s disease. Fellows are encouraged to be involved in these collaborations in order to develop their own expertise and independent research.

Fellows are encouraged to take courses from the Washington University Clinical Research Training Center with an opportunity to pursue a Graduate Certificate or Masters Degree. Up to 50% tuition reimbursement is provided. Travel to present research at one national or international meeting (up to $2000) is provided. For fellows who have completed an ACGME accredited residency or fellowship, up to 33% clinical effort may potentially be arranged.